2025-05-18-Jefferies-全球健康有限公司（MEDANTA）_重回增长轨道_维持买入_13页_664kb

Medanta Summary: Investment Analysis and Key Insights

Core Content

Medanta, a leading Indian private hospital chain, reported its fourth-quarter financial results for FY25, showing revenue growth of 15% YoY but a lower-than-expected EBITDA due to lower occupancy and higher operating expenses. Despite this, the company remains optimistic about its growth trajectory, driven by volume increases and new hospital projects.

Main Points

4QFY25 Performance

• Revenue: INR9.3bn (+15% YoY/-1% QoQ), in line with estimates.
• EBITDA: INR2.25bn (+18% YoY/-7% QoQ), 5% below estimates.
• PAT: INR1bn (-20% YoY/-29% QoQ), 19% below estimates due to an exceptional item of INR0.5bn.
• ARPOB: INR63.6k/day, flat YoY.
• Occupancy: 61%, below the estimate of 63%.
• EBITDA Margin: 24.1%, below the expected 25.4% due to higher opex.

Volume-Driven Growth

• IPD Volume Growth: 15% YoY.
• OPD Growth: 13% YoY.
• Occupied Bed Days: 12% YoY increase.
• Impact of Mahakumbh Event: Occupancy and volume saw downward pressure due to the event.
• Near-Term Growth Drivers: Continued traction in Lucknow and Patna, new bed additions in Ranchi, and planned price hikes in select hospitals and therapies.

New Projects

• Guwahati: A new hospital with 400+ beds, with land purchase of 3 acres for INR300m and estimated construction cost of INR5.1bn.
• Noida: Superstructure completed; 300 beds expected to start operations in 2QFY26.
• Ranchi: 110 beds expected to begin operations in 1QFY26, with full capacity of 550 beds.
• South Delhi Hospital: Basic construction started after a delay of over 12 months.
• Pitampura Hospital: Construction to commence once permits are received, with 750 bed capacity.
• Project Timeline: All projects except Noida are expected to take 3–4 years to begin operations.

Investment Thesis

• Maintain Buy Rating: Due to expected improvement in growth rates to high teens, driven by volume growth.
• Price Target: INR1,380, with a 15% increase from the current price.
• Valuation: Based on 32x FY27E EBITDA.
• Outlook: FY25 was a growth hiatus, with EBITDA growth expected to improve to mid-teens in FY26–27.

Key Metrics (FY25–2028E)

EBITDA and Revenue Growth

• FY25–27E Revenue Growth: 14%.
• FY25–27E EBITDA Growth: 14%.
• Up/Downside Scenarios:
  • Up: INR1,510 (+26%), 16% revenue growth, 16% EBITDA growth.
  • Down: INR1,060 (-12%), 12% revenue growth, 12% EBITDA growth.

Key Risks and Considerations

• High Dependence on Dr. Naresh Trehan: The company's growth is heavily reliant on the leadership of the Chairperson.
• Competition in Delhi-NCR: Increasing competition in the region may affect performance.
• Execution Risks: Challenges in ramping up operations in Lucknow and Patna.
• Affordability Concerns: Lower affordability in non-metro cities like Patna may limit patient base.
• Debt and Liquidity: Net debt/equity ratio is negative, indicating strong liquidity.

Analysts and Certification

• Analysts: Alok Dalal (Equity Analyst), Dhawal Khut (Equity Associate).
• Certification: Both analysts certify that their views reflect personal opinions and are not influenced by compensation.

Company Overview

• Location: Operates 5 hospitals in Central and Northern India.
• Founder: Dr. Naresh Trehan, a renowned cardiologist.
• Bed Capacity: Over 2,400 beds across its hospitals.
• Notable Achievement: Gurugram hospital ranked as the best private hospital in India for 2020 and 2021 by Newsweek.
• Clinics: Five multi-specialty clinics in key locations.

Valuation Methodology

• Price Target: Based on multiple methodologies including DCF, EBITDA, EPS, and EV/EBITDA.
• Ratings: Buy, Hold, Underperform, based on expected total return over the next 12 months.

Investment Recommendation

• Buy Rating: Indicates expected total return of 15% or more over the next 12 months.
• Price Target: INR1,380, representing a 15% increase from the current price.

Summary of Key Insights

• Medanta's 4QFY25 results were slightly below expectations due to lower occupancy and higher opex, but volume growth remained strong.
• New hospital projects in Guwahati, Lucknow, and Patna are expected to drive future growth.
• The company plans to implement price hikes in FY26, aligned with inflation trends.
• The valuation is based on 32x FY27E EBITDA, with a price target of INR1,380.
• Analysts note the importance of maintaining volume growth and addressing affordability challenges in new markets.
• Risks include high reliance on leadership, competition, and execution challenges in new hospital launches.